Cited by 502Sepsis Diagnosis and TreatmentAntibiotics Pharmacokinetics and EfficacyAcute Kidney Injury Research

The DOI matches its Crossref record; 23 of the 25 references it cites were found in a registry or an index.

Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial

Open access

Dellinger, R. Phillip, Bagshaw, Sean M., Antonelli, Massimo, Foster, Debra M., Klein, David J., Marshall, John C., Palevsky, Paul M., Weisberg, Lawrence S., Schorr, Christa A., Trzeciak, Stephen, Walker, Paul M., for the EUPHRATES Trial Investigators·2018·JAMA

DOI 10.1001/jama.2018.14618PMC PMC6233793

Open this paper in CoChat — free account Open PDF

Abstract

Importance: Polymyxin B hemoperfusion reduces blood endotoxin levels in sepsis. Endotoxin activity can be measured in blood with a rapid assay. Treating patients with septic shock and elevated endotoxin activity using polymyxin B hemoperfusion may improve clinical outcomes. Objective: To test whether adding polymyxin B hemoperfusion to conventional medical therapy improves survival compared with conventional therapy alone among patients with septic shock and high endotoxin activity. Design, Setting, and Participants: Multicenter, randomized clinical trial involving 450 adult critically ill patients with septic shock and an endotoxin activity assay level of 0.60 or higher enrolled between September 2010 and June 2016 at 55 tertiary hospitals in North America. Last follow-up was June 2017. Interventions: Two polymyxin B hemoperfusion treatments (90-120 minutes) plus standard therapy completed within 24 hours of enrollment (n = 224 patients) or sham hemoperfusion plus standard therapy (n = 226 patients). Main Outcomes and Measures: The primary outcome was mortality at 28 days among all patients randomized (all participants) and among patients randomized with a multiple organ dysfunction score (MODS) of more than 9. Results: Among 450 eligible enrolled patients (mean age, 59.8 years; 177 [39.3%] women; mean APACHE II score 29.4 [range, 0-71 with higher scores indicating greater severity), 449 (99.8%) completed the study. Polymyxin B hemoperfusion was not associated with a significant difference in mortality at 28 days among all participants (treatment group, 84 of 223 [37.7%] vs sham group 78 of 226 [34.5%]; risk difference [RD], 3.2%; 95% CI, -5.7% to 12.0%; relative risk [RR], 1.09; 95% CI, 0.85-1.39; P = .49) or in the population with a MODS of more than 9 (treatment group, 65 of 146 [44.5%] vs sham, 65 of 148 [43.9%]; RD, 0.6%; 95% CI, -10.8% to 11.9%; RR, 1.01; 95% CI, 0.78-1.31; P = .92). Overall, 264 serious adverse events were reported (65.1% treatment group vs 57.3% sham group). The most frequent serious adverse events were worsening of sepsis (10.8% treatment group vs 9.1% sham group) and worsening of septic shock (6.6% treatment group vs 7.7% sham group). Conclusions and Relevance: Among patients with septic shock and high endotoxin activity, polymyxin B hemoperfusion treatment plus conventional medical therapy compared with sham treatment plus conventional medical therapy did not reduce mortality at 28 days. Trial Registration: ClinicalTrials.gov Identifier: NCT01046669.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/jama.2018.14618

Cites

23 of 23 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock
Dellinger, R. P., Levy, M. M., Rhodes, A., Annane, D., Gerlach, H., Opal, S. M., Sevransky, J. E., Sprung, C. L., Douglas, I. S., Jaeschke, R., et al. (2013) · Critical Care Medicine · doi:10.1097/ccm.0b013e31827e83af · Cited by 9,694
Self-citation
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock, 2012
Dellinger, R. P., Levy, M. M., Rhodes, A., Annane, D., Gerlach, H., Opal, S. M., Sevransky, J., Sprung, C. L., Douglas, I. S., Jaeschke, R., et al. (2013) · Intensive Care Medicine · doi:10.1007/s00134-012-2769-8 · Cited by 7,371
Self-citation
Intravenous Fluids and Acute Kidney Injury
Ding, X., Cheng, Z., & Qian, Q. (2017) · Blood Purification · doi:10.1159/000452702 · Cited by 6,869
Early Use of Polymyxin B Hemoperfusion in Abdominal Septic Shock
Cruz, D. N., Antonelli, M. M., Fumagalli, R., Foltran, F., Brienza, N., Donati, A., Malcangi, V., Petrini, F., Volta, G., Pallavicini, F. M. B., et al. (2009) · JAMA · doi:10.1001/jama.2009.856 · Cited by 841
Self-citation
Effect of Eritoran, an Antagonist of MD2-TLR4, on Mortality in Patients With Severe Sepsis: The ACCESS Randomized Trial
Opal, S. M., Laterre, P.-F., Francois, B., LaRosa, S. P., Angus, D. C., Mira, J.-P., Wittebole, X., Dugernier, T., Perrotin, D., Tidswell, M., et al. (2013) · JAMA · doi:10.1001/jama.2013.2194 · Cited by 812
Relationship between Plasma Levels of Lipopolysaccharide (LPS) and LPS‐Binding Protein in Patients with Severe Sepsis and Septic Shock
Opal, S. M., Scannon, P. J., Vincent, J., White, M., Carroll, S. F., Palardy, J. E., Parejo, N. A., Pribble, J. P., & Lemke, J. H. (1999) · The Journal of Infectious Diseases · doi:10.1086/315093 · Cited by 609
Surviving Sepsis Campaign
Levy, M. M., Rhodes, A., Phillips, G. S., Townsend, S. R., Schorr, C., Beale, R. J., Osborn, T. M., Lemeshow, S. A., Chiche, J., Artigas, A., et al. (2014) · Critical Care Medicine · doi:10.1097/ccm.0000000000000723 · Cited by 583
Self-citation
Treatment of Septic Shock with Human Monoclonal Antibody HA-1A
McCloskey, R. V., Straube, R. C., Sanders, C., Smith, S. M., Smith, C. R., & and CHESS Trial Study Group. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-1-199407010-00001 · Cited by 492
Early use of polymyxin B hemoperfusion in patients with septic shock due to peritonitis: a multicenter randomized control trial
The ABDOMIX Group, Payen, D. M., Guilhot, J., Launey, Y., Lukaszewicz, A. C., Kaaki, M., Veber, B., Pottecher, J., Joannès-Boyau, O., Martin‐Lefèvre, L., et al. (2015) · Intensive Care Medicine · doi:10.1007/s00134-015-3751-z · Cited by 418
Recombinant bactericidal/permeability-increasing protein (rBPI21) as adjunctive treatment for children with severe meningococcal sepsis: a randomised trial
Levin, M., Quint, P. A., Goldstein, B., Barton, P., Bradley, J. S., Shemie, S., Yeh, T. S., Kim, S. S., Cafaro, D. P., Scannon, P. J., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02712-4 · Cited by 408

Flagged first, then by citations

Show all 25 references

2 of the 25 references couldn’t be matched to a known paper.

Sorted by citations

Items 101–200 of 501

The dangerous liaisons in innate immunity involving recombinant proteins and endotoxins: Examples from the literature and the Leptospira field
Bonhomme, D., Cavaillon, J., & Werts, C. (2023) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2023.105506 · Cited by 31
S3-Leitlinie Sepsis – Prävention, Diagnose, Therapie und Nachsorge – Update 2025
Brunkhorst, F. M., Adamzik, M., Axer, H., Bauer, M. W., Bode, C., Bone, H.-G., Brenner, T., Bucher, M., David, S., Dietrich, M., et al. (2025) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-025-01317-1 · Cited by 35
Charge-biased nanofibrous membranes with uniform charge distribution and hemocompatibility for enhanced selective adsorption of endotoxin from plasma
Dou, W., Qi, F., Li, Y., Wei, F., Hu, Q., Yao, Z., Wang, J., Zhang, L., & Tang, Z. N. (2022) · Journal of Membrane Science · doi:10.1016/j.memsci.2022.121134 · Cited by 28
Advances in the Development of Biomaterials for Endotoxin Adsorption in Sepsis
Yang, Q., Li, Y., Tuohuti, P., Qin, Z., Zhang, Z., Zhao, W., & Su, B. (2021) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2021.699418 · Cited by 27
Overcoming barriers in the design and implementation of clinical trials for acute kidney injury: a report from the 2020 Kidney Disease Clinical Trialists meeting
Lazzareschi, D. V., Mehta, R. L., Dember, L. M., Bernholz, J., Turan, A., Sharma, A. K., Kheterpal, S., Parikh, C. R., Ali, O., Schulman, I. H., et al. (2022) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfac003 · Cited by 30
Targeting circulating high mobility group box-1 and histones by extracorporeal blood purification as an immunomodulation strategy against critical illnesses
Li, Y., Chen, Y., Yang, T., Chang, K., Deng, N., Zhao, W., & Su, B. (2023) · Critical Care · doi:10.1186/s13054-023-04382-0 · Cited by 27
HEMOPERFUSION USING THE LPS-SELECTIVE MESOPOROUS POLYMERIC ADSORBENT IN SEPTIC SHOCK: A MULTICENTER RANDOMIZED CLINICAL TRIAL
Rey, S. I., Кулабухов, В. В., Popov, A., Nikitina, O., Анатольевич, Б. Г., Магомедов, М. А., Kim, T., Викторович, М. С., Игнатенко, О. В., Кротенко, Н. П., et al. (2023) · Shock · doi:10.1097/shk.0000000000002121 · Cited by 27
Bacterial extracellular vesicles repress the vascular protective factor RNase1 in human lung endothelial cells
Laakmann, K., Eckersberg, J. M., Hapke, M., Wiegand, M., Bierwagen, J., Beinborn, I., Preußer, C., von Strandmann, E. P., Heimerl, T., Schmeck, B., et al. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01131-2 · Cited by 27
Endotoxin Removal in Septic Shock with the Alteco LPS Adsorber Was Safe But Showed no Benefit Compared to Placebo in the Double-Blind Randomized Controlled Trial—the Asset Study
Lipcsey, M., Tenhunen, J. J., Pischke, S. E., Kuitunen, A., Flaatten, H. K., Geer, L. D., Sjölin, J., Frithiof, R., Chew, M. S., Bendel, S., et al. (2019) · Shock · doi:10.1097/shk.0000000000001503 · Cited by 26
Peripheral neuropathy in severe COVID‐19 resolved with therapeutic plasma exchange
Faqihi, F. A., Alharthy, A. M., Memish, Z. A., Kutsogiannis, D. J., Brindley, P. G., & Karakitsos, D. (2020) · Clinical Case Reports · doi:10.1002/ccr3.3397 · Cited by 24
Endotoxin Mass Concentration in Plasma Is Associated With Mortality in a Multicentric Cohort of Peritonitis-Induced Shock
Payen, D. M., Dupuis, C., Deckert, V., de Barros, J.-P. P., Rérole, A.-L., Lukaszewicz, A., Coudroy, R., Robert, R., & Lagrost, L. (2021) · Frontiers in Medicine · doi:10.3389/fmed.2021.749405 · Cited by 27
Application of oXiris-continuous hemofiltration adsorption in patients with sepsis and septic shock: A single-centre experience in China
Zhou, Y.-Y., Wu, C.-F., Ouyang, L., Peng, Y., Zhong, D., Xiang, X.-H., & Li, J. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.1012998 · Cited by 23
Endotoxemia in Acute Heart Failure and Cardiogenic Shock: Evidence, Mechanisms and Therapeutic Options
Nguyen, M., Gautier, T., Masson, D., Bouhemad, B., & Guinot, P.-G. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12072579 · Cited by 25
Challenges in Septic Shock: From New Hemodynamics to Blood Purification Therapies
Rueda, F. R., Nieves‐Alonso, J., Villabona, E. G., Vallejo, C., Kattan, E., & Méndez, R. (2024) · Journal of Personalized Medicine · doi:10.3390/jpm14020176 · Cited by 24
Current perspectives in the management of sepsis and septic shock
Chiscano‐Camón, L., Ruiz‐Sanmartín, A., Bajaña, I., Bastidas, J., López‐Martínez, R., Franco‐Jarava, C., González‐López, J. J., Larrosa, N., Riera, J., Nuvials, X., et al. (2024) · Frontiers in Medicine · doi:10.3389/fmed.2024.1431791 · Cited by 30
Options in extracorporeal support of multiple organ failure
Huber, W., & de Garibay, A. P. R. (2020) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/s00063-020-00658-3 · Cited by 26
Sepsis Management for the Nephrologist
Patel, S., Puri, N., & Dellinger, R. P. (2022) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.14381121 · Cited by 28
Self-citation
Novel aspects of sepsis pathophysiology: NETs, plasma glycoproteins, endotheliopathy and COVID-19
Nishibori, M. (2022) · Journal of Pharmacological Sciences · doi:10.1016/j.jphs.2022.06.001 · Cited by 25
Gaps and opportunities in sepsis translational research
Marshall, J. C., & Leligdowicz, A. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104387 · Cited by 28
Self-citation
Effect of Duration of Macular Detachment on Visual Prognosis after Surgery for Macula-Off Retinal Detachment
Miyake, M., Nakao, S., Morino, K., Yasukura, S., Mori, Y., Ishihara, K., Muraoka, Y., Miyata, M., Tamura, H., Sakamoto, T., et al. (2023) · Ophthalmology Retina · doi:10.1016/j.oret.2023.01.014 · Cited by 24
Plasma exchange in the treatment of complex COVID-19-related critical illness: controversies and perspectives
Memish, Z. A., Faqihi, F. A., Alharthy, A. M., Alqahtani, S. A., & Karakitsos, D. (2020) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2020.106273 · Cited by 23
Molecular Mechanisms of Sepsis-Associated Acute Kidney Injury
Hato, T., & Dagher, P. C. (2025) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000000809 · Cited by 24
Predictive enrichment using biomarkers in studies of critically-ill patients with sepsis: a systematic review
Nynatten, L. R. V., Bokhary, D. H., Wong, M. Y. S., Wang, J., Fero, H., McChesney, C., Fiorini, K., Blake, L., Fraser, D. D., Slessarev, M., et al. (2025) · Critical Care · doi:10.1186/s13054-025-05684-1 · Cited by 23
Extracorporeal Hemoperfusion as a Potential Therapeutic Option for Severe COVID-19 patients; a Narrative Review.
Safari, S., Salimi, A., Zali, A., Jahangirifard, A., Bastanhagh, E., Aminnejad, R., Dabbagh, A., Lotfi, A. H., & Saeidi, M. (2020) · Europe PMC (PubMed Central) · Cited by 23
Bacterial endotoxins and exotoxins in intensive care medicine
Sheehan, J. R., Sadlier, C., & O'Brien, B. (2022) · BJA Education · doi:10.1016/j.bjae.2022.01.003 · Cited by 23
The wind changed direction and the big river still flows: from EUPHRATES to TIGRIS
Iba, T., & Klein, D. J. (2019) · Journal of Intensive Care · doi:10.1186/s40560-019-0386-0 · Cited by 23
Self-citation
Sex and gender-based analysis and diversity metric reporting in acute care trials published in high-impact journals: a systematic review
Granton, D., Rodrigues, M., Raparelli, V., Honarmand, K., Agarwal, A., Friedrich, J. O., Perna, B., Spaggiari, R., Fortunato, V., Risdonne, G., et al. (2024) · BMJ Open · doi:10.1136/bmjopen-2023-081118 · Cited by 27
Evolving Paradigms in Sepsis Management: A Narrative Review
Kim, M., Choi, E.-J., & Choi, E.-J. (2024) · Cells · doi:10.3390/cells13141172 · Cited by 24
Cytokine storms, evolution and COVID-19
Alcock, J., & Masters, A. (2021) · Evolution Medicine and Public Health · doi:10.1093/emph/eoab005 · Cited by 20
Continuous renal replacement therapy under special conditions like sepsis, burn, cardiac failure, neurotrauma, and liver failure
Davenport, A., & Honoré, P. M. (2021) · Seminars in Dialysis · doi:10.1111/sdi.13002 · Cited by 25
Navigating the Modern Landscape of Sepsis: Advances in Diagnosis and Treatment
Jang, J. H., Choi, E., Kim, T., Yeo, H. J., Jeon, D., Kim, Y. S., & Cho, W. H. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25137396 · Cited by 21
Association of immediate reinsertion of new catheters with subsequent mortality among patients with suspected catheter infection: a cohort study
Zhong, Y., Deng, L., Zhou, L., Liao, S., Yue, L., Wen, S. W., Xie, R., Lu, Y., Zhang, L., Tang, J., et al. (2022) · Annals of Intensive Care · doi:10.1186/s13613-022-01014-8 · Cited by 22
Life-threatening COVID-19 presenting as stroke with antiphospholipid antibodies and low ADAMTS-13 activity, and the role of therapeutic plasma exchange: A case series
Alharthy, A. M., Faqihi, F. A., Balhamar, A., Memish, Z. A., & Karakitsos, D. (2020) · SAGE Open Medical Case Reports · doi:10.1177/2050313x20964089 · Cited by 21
Expanding the potential therapeutic options of hemoperfusion in the era of improved sorbent biocompatibility
Damianaki, A., Stambolliu, E., Alexakou, Z., & Petras, D. I. (2023) · Kidney Research and Clinical Practice · doi:10.23876/j.krcp.22.223 · Cited by 20
Effects of enhanced adsorption haemofiltration versus haemoadsorption in severe, refractory septic shock with high levels of endotoxemia: the ENDoX bicentric, randomized, controlled trial
Wendel‐Garcia, P. D., Eberle, B. M., Kleinert, E.-M., Hilty, M. P., Blumenthal, S., Spanaus, K. S., Fodor, P., & Maggiorini, M. (2023) · Annals of Intensive Care · doi:10.1186/s13613-023-01224-8 · Cited by 20
Biomarker Enrichment in Sepsis-Associated Acute Kidney Injury: Finding High-Risk Patients in the Intensive Care Unit
Baeseman, L. G., Gunning, S., & Koyner, J. L. (2023) · American Journal of Nephrology · doi:10.1159/000534608 · Cited by 22
Haemoadsorption to remove inflammatory mediators in sepsis: past, present, and future
Waalders, N. J. B., Kox, M., & Pickkers, P. (2025) · Intensive Care Medicine Experimental · doi:10.1186/s40635-025-00740-0 · Cited by 24
Potential survival benefit and early recovery from organ dysfunction with polymyxin B hemoperfusion: perspectives from a real-world big data analysis and the supporting mechanisms of action
Shoji, H., & Ferrer, R. (2022) · Journal of Anesthesia Analgesia and Critical Care · doi:10.1186/s44158-022-00056-5 · Cited by 20
Surviving Sepsis Campaign: Research Opportunities for Infection and Blood Purification Therapies
Martín‐Loeches, I., Nunnally, M., Hellman, J., Lat, I., Martin, G. S., Jog, S., Kesecioğlu, J., Backer, D. D., & Coopersmith, C. M. (2021) · Critical Care Explorations · doi:10.1097/cce.0000000000000511 · Cited by 20
The History of Biomarkers: How Far Have We Come?
Lachmann, G., & Reinhart, K. (2020) · Critical care clinics · doi:10.1016/j.ccc.2019.08.001 · Cited by 3
Management of Acute Kidney Injury in Coronavirus Disease 2019
Shaikh, S. J., Umemoto, G. M., & Vijayan, A. (2020) · Advances in Chronic Kidney Disease · doi:10.1053/j.ackd.2020.08.002 · Cited by 19
The Techniques of Blood Purification in the Treatment of Sepsis and Other Hyperinflammatory Conditions
Berlot, G., Tomasini, A., Zanchi, S., & Moro, E. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12051723 · Cited by 18
Endotoxin activity trend and multi‐organ dysfunction in critically ill patients with septic shock, who received Polymyxin‐B hemadsorption: A multicenter, prospective, observational study
Cutuli, S. L., Rosa, S. D., Ferrer, R., Ruiz‐Rodríguez, J. C., Forfori, F., Ronco, C., Antonelli, M. M., & the EUPHAS2‐G50 Collaborative Study Group (2023) · Artificial Organs · doi:10.1111/aor.14534 · Cited by 18
Self-citation
Bayesian methods: a potential path forward for sepsis trials
TOMLINSON, G. A., Al-Khafaji, A. H., Conrad, S. A., Factora, F. N., Foster, D., Galphin, C. M., Gunnerson, K. J., Khan, S., Kohli-Seth, R. D., McCarthy, P. J., et al. (2023) · Critical Care · doi:10.1186/s13054-023-04717-x · Cited by 19
Self-citation
Modern extracorporeal methods for critical conditions caused by systemic inflammatory response (review)
Рубцов, М. С., & SHUKEVICH, D. L. (2019) · Russian Journal of Anesthesiology and Reanimatology · doi:10.17116/anaesthesiology201904120 · Cited by 18
Results of the 2018 Japan Society for Blood Purification in Critical Care survey: current status and outcomes
Abe, M., Shiga, H., Tatsumi, H., Endo, Y., Kikuchi, Y., Suzuki, Y. A., Doi, K., Nakada, T., Nagafuchi, H., Hattori, N., et al. (2022) · Renal Replacement Therapy · doi:10.1186/s41100-022-00445-0 · Cited by 17
Liver replacement therapy with extracorporeal blood purification techniques current knowledge and future directions
Papamichalis, P. A., Oikonomou, K. G., Valsamaki, A., Xanthoudaki, M., Katsiafylloudis, P., Papapostolou, E., Skoura, A.-L., Papamichalis, M., Karvouniaris, M., Koutras, A., et al. (2023) · World Journal of Clinical Cases · doi:10.12998/wjcc.v11.i17.3932 · Cited by 17
Septic Hyperinflammation—Is There a Role for Extracorporeal Blood Purification Techniques?
Jarczak, D., Kluge, S., & Nierhaus, A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063120 · Cited by 17
The role of polymyxin B-immobilized hemoperfusion in reducing mortality and enhancing hemodynamics in patients with sepsis and septic shock: A systematic review and meta-analysis
Li, C., Zhang, J., Yang, P., Wang, R., Chen, T., & LiXia, L. I. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e33735 · Cited by 17
Comparative Evaluation of Endotoxin Activity Level and Various Biomarkers for Infection and Outcome of ICU-Admitted Patients
Ikeda, T., Kamohara, H., Suda, S., Nagura, T., Tomino, M., Sugi, M., & Wajima, Z. (2019) · Biomedicines · doi:10.3390/biomedicines7030047 · Cited by 17
The application value of oXiris-endotoxin adsorption in sepsis.
Zhai, Y., Pan, J., & Zhang, C. (2021) · PubMed Central · Cited by 17
Focus on sepsis
Møller, M. H., Alhazzani, W., & Shankar-Hari, M. (2019) · Intensive Care Medicine · doi:10.1007/s00134-019-05680-4 · Cited by 17
Controversies in Sepsis Management—What is the Way Forward?
Lo, A. H., Kee, A. C. L., Li, A., & Rubulotta, F. M. (2020) · Annals of the Academy of Medicine Singapore · doi:10.47102/annals-acadmedsg.202090 · Cited by 16
Impact of Extended Duration of Polymyxin B-Immobilized Fiber Column Direct Hemoperfusion on Hemodynamics, Vasoactive Substance Requirement, and Pulmonary Oxygenation in Patients with Sepsis: An Observational Study
Mitaka, C., Kusao, M., Kawagoe, I., Satoh, D., Iba, T., & Ronco, C. (2021) · Blood Purification · doi:10.1159/000515685 · Cited by 16
Endotoxemia in Critically Ill Patients with COVID-19
Khan, S., Bolotova, O., Sahib, H., Foster, D., & Mallipattu, S. K. (2021) · Blood Purification · doi:10.1159/000518230 · Cited by 16
Self-citation
Blood purification in sepsis and COVID-19: what´s new in cytokine and endotoxin hemoadsorption
Ruiz‐Rodríguez, J. C., Plata-Menchaca, E. P., Chiscano‐Camón, L., Ruiz‐Sanmartín, A., & Ferrer, R. (2022) · Journal of Anesthesia Analgesia and Critical Care · doi:10.1186/s44158-022-00043-w · Cited by 16
Polymyxin B Hemoperfusion in Pediatric Septic Shock: Single-Center Observational Case Series
Saetang, P., Samransamruajkit, R., Singjam, K., & Deekajorndech, T. (2022) · Pediatric Critical Care Medicine · doi:10.1097/pcc.0000000000002969 · Cited by 16
The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2024
Shime, N., Nakada, T., Yatabe, T., Yamakawa, K., Aoki, Y., Inoue, S., Iba, T., Ogura, H., Kawai, Y., Kawaguchi, A., et al. (2025) · Acute Medicine & Surgery · doi:10.1002/ams2.70037 · Cited by 20
Impact of plasma 5-hydroxyindoleacetic acid, a serotonin metabolite, on clinical outcome in septic shock, and its effect on vascular permeability
Tanaka, T., Mori, M., Sekino, M., Higashijima, U., Takaki, M., Yamashita, Y., Kakiuchi, S., Tashiro, M., Morimoto, K., Tasaki, O., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-93649-z · Cited by 17
Impact of polymyxin B hemoperfusion therapy on high endotoxin activity level patients after successful infection source control: a prospective cohort study
Lee, W. Y., Kim, H., & Kim, E. Y. (2021) · Scientific Reports · doi:10.1038/s41598-021-03055-8 · Cited by 16
Effectiveness of Reduced-fluence Photodynamic Therapy for Chronic Central Serous Chorioretinopathy
Aisu, N., Miyake, M., Hosoda, Y., Mori, Y., Takahashi, A., Muraoka, Y., Ueda‐Arakawa, N., Miyata, M., Oishi, A., Tamura, H., et al. (2022) · Ophthalmology Science · doi:10.1016/j.xops.2022.100152 · Cited by 16
Impact of hemoperfusion with polymyxin B added to hemofiltration in patients with endotoxic shock: a case–control study
Navas, A., Ferrer, R., Martínez, M. L., Gomà, G., Gili, G., Masip, J., Suarez, D. L., & Artigas, A. (2018) · Annals of Intensive Care · doi:10.1186/s13613-018-0465-8 · Cited by 16
Pathogen characteristics are key determinants of distinct host response phenotypes of sepsis
Chanderraj, R., Bartek, B., Stringer, K. A., Tiba, M. H., Sjoding, M. W., He, Y., Nuppnau, M., Bongers, K. S., Adame, M. D., Lou, S. S., et al. (2026) · Journal of Clinical Investigation · doi:10.1172/jci197346 · Cited by 16
Self-citation
Current clinical practice in using adjunctive extracorporeal blood purification in sepsis and septic shock: results from the ESICM “EXPLORATION” survey
Stahl, K., Bode, C., Seeliger, B., Wendel‐Garcia, P. D., & David, S. (2024) · Intensive Care Medicine Experimental · doi:10.1186/s40635-023-00592-6 · Cited by 15
The effect of direct hemoperfusion with polymyxin B immobilized cartridge on meropenem in critically ill patients requiring renal support
Singhan, W., Vadcharavivad, S., Areepium, N., Wittayalertpanya, S., Chaijamorn, W., & Srisawat, N. (2019) · Journal of Critical Care · doi:10.1016/j.jcrc.2019.02.007 · Cited by 15
Targeting of G-protein coupled receptors in sepsis
Rehman, A., Baloch, N. U.-A., Morrow, J., Pacher, P., & Haskó, G. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107529 · Cited by 18
Extracorporeal Therapy in Sepsis
Praveen, G. (2015) · Indian Journal of Critical Care Medicine · doi:10.5005/jp-journals-10071-23382 · Cited by 14
Endotoxin and Cytokine Sequential Hemoadsorption in Septic Shock and Multi-Organ Failure
Ruiz‐Rodríguez, J. C., Chiscano‐Camón, L., Palmada, C., Ruiz‐Sanmartín, A., Pérez-Carrasco, M., Larrosa, N., González‐López, J. J., Hernández-González, M., & Ferrer, R. (2021) · Blood Purification · doi:10.1159/000518229 · Cited by 14
Endotoxemic Shock: A Molecular Phenotype in Sepsis
Kellum, J. A., Foster, D., & Walker, P. M. (2022) · The Nephron journals/Nephron journals · doi:10.1159/000525548 · Cited by 15
Self-citation
Endotoxin removal therapy with Polymyxin B immobilized fiber column: a single center experience from EUPHAS2 registry
Forin, E., Lorenzoni, G., Ferrer, R., de Cal, M., Zanella, M., Marchionna, N., Gregori, D., Forfori, F., Lorenzin, A., Danzi, V., et al. (2023) · Scientific Reports · doi:10.1038/s41598-023-44850-9 · Cited by 18
Sepsis in 2024: a review
Wayland, J., Teixeira, J. P., & Nielsen, N. D. (2024) · Anaesthesia & intensive care medicine · doi:10.1016/j.mpaic.2024.06.010 · Cited by 16
Comparison of the circulatory effects of continuous renal replacement therapy using AN69ST and polysulfone membranes in septic shock patients: A retrospective observational study
Shibata, M., Miyamoto, K., & Kato, S. (2019) · Therapeutic Apheresis and Dialysis · doi:10.1111/1744-9987.13462 · Cited by 14
Identifying Septic Shock Populations Benefitting From Polymyxin B Hemoperfusion: A Prospective Cohort Study Incorporating a Restricted Cubic Spline Regression Model
Nakata, H., Yamakawa, K., Kabata, D., Umemura, Y., Ogura, H., Gando, S., Shintani, A., Shiraishi, A., Saitoh, D., Fujishima, S., et al. (2020) · Shock · doi:10.1097/shk.0000000000001533 · Cited by 14
Haemoperfusion should only be used for COVID-19 in the context of randomized trials
Clark, E. G., Hiremath, S. S., McIntyre, L., Wald, R., Hundemer, G. L., & Joannidis, M. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-00352-9 · Cited by 15
Sequential Extracorporeal Blood Purification Is Associated with Prolonged Survival among ICU Patients with COVID-19 and Confirmed Bacterial Superinfection
Premužić, V., Šitum, I., Lovrić, D., Erceg, A., Karmelić, D., Moguš, M., Jurjević, M., Nedeljković, V., Mažar, M., Mihaljević, S., et al. (2023) · Blood Purification · doi:10.1159/000531356 · Cited by 13
Proceedings of the 2022 UAB CRRT Academy: Non-Invasive Hemodynamic Monitoring to Guide Fluid Removal with CRRT and Proliferation of Extracorporeal Blood Purification Devices
Teixeira, J. P., Zeidman, A. D., Beaubien‐Souligny, W., Cerdá, J., Connor, M. J., Jr., Eggleston, K., Juncos, L. A., Silva, J. R. D., Wells, C., Yessayan, L., et al. (2023) · Blood Purification · doi:10.1159/000533573 · Cited by 15
Causal inference can lead us to modifiable mechanisms and informative archetypes in sepsis
Baillie, J. K., Angus, D. C., Burnham, K. L., Calandra, T., Calfee, C. S., Gutteridge, A., Hacohen, N., Khatri, P., Langley, R. J., Ma’ayan, A., et al. (2024) · Intensive Care Medicine · doi:10.1007/s00134-024-07665-4 · Cited by 13
Self-citation
HDL Cholesterol: A “Pathogen Lipid Sink” for Sepsis?
Jones, T. K., Wong, H. R., & Meyer, N. J. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201811-2084ed · Cited by 13
Acute Kidney Injury in Sepsis: Evidence From Asia
Yoshimoto, K., Komaru, Y., Iwagami, M., & Doi, K. (2020) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2020.08.005 · Cited by 13
Distinct host-response signatures in circulatory shock: a narrative review
Soussi, S., dos Santos, C. C., Jentzer, J. C., Mebazaa, A., Gayat, É., Pöss, J., Schaubroeck, H., Billia, F., Marshall, J. C., & Lawler, P. R. (2023) · Intensive Care Medicine Experimental · doi:10.1186/s40635-023-00531-5 · Cited by 13
Self-citation
Importance of Endotoxin Clearance in Endotoxemic Septic Shock: An Analysis From the Evaluating Use of PolymyxinB Hemoperfusion in a Randomized Controlled Trial of Adults Treated for Endotoxemic Septic Shock (EUPHRATES) Trial
Rachoin, J.-S., Foster, D., Giese, R., Weisberg, L. S., & Klein, D. J. (2020) · Critical Care Explorations · doi:10.1097/cce.0000000000000083 · Cited by 13
Self-citation
Extrakorporale Blutreinigungsverfahren in der Sepsis – Update
Seeliger, B., Stahl, K., & David, S. (2020) · Der Internist · doi:10.1007/s00108-020-00862-5 · Cited by 13
Up-to-date information on polymyxin B-immobilized fiber column direct hemoperfusion for septic shock
Mitaka, C., Kusaoi, M., Kawagoe, I., & Satoh, D. (2021) · Acute and Critical Care · doi:10.4266/acc.2021.00150 · Cited by 12
Wnt-Signaling Inhibitor Wnt-C59 Suppresses the Cytokine Upregulation in Multiple Organs of Lipopolysaccharide-Induced Endotoxemic Mice via Reducing the Interaction between β-Catenin and NF-κB
Jang, J., Song, J., Sim, I., Kwon, Y. V., & Yoon, Y. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22126249 · Cited by 12
Macrophage activation syndrome in Sepsis: from pathogenesis to clinical management
Chen, S., Zhang, C., Luo, J., Lin, Z., Chang, T., Dong, L., Chen, D., & Tang, Z. (2024) · Inflammation Research · doi:10.1007/s00011-024-01957-7 · Cited by 12
Eligibility Criteria of Randomized Clinical Trials in Critical Care Medicine
Heirali, A., Heybati, K., Sereeyotin, J., Khan, F. A., Yarnell, C. J., Krewulak, K. D., Murthy, S., Burns, K. E. A., Fowler, R., Fiest, K. M., et al. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2024.54944 · Cited by 12
Extracorporeal therapies in sepsis: a comprehensive review of the Selective Cytopheretic Device, Polymyxin B and Seraph cartridges
Yessayan, L., Pino, C. J., & Humes, H. D. (2025) · Renal Failure · doi:10.1080/0886022x.2025.2459349 · Cited by 12
“Impact of timing of polymyxin B‐immobilized fiber column direct hemoperfusion on outcome in patients with septic shock: a single‐center observational study”
Tanaka, T., Tabata, T., Fujino, K., Tsujita, Y., & Eguchi, Y. (2019) · Acute Medicine & Surgery · doi:10.1002/ams2.446 · Cited by 12
Chasing the Ghost: Hyperinflammation Does Not Cause Sepsis
Shapiro, L., Scherger, S. J., Franco‐Paredes, C., Gharamti, A. A., Fraulino, D., & Henao‐Martínez, A. F. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.910516 · Cited by 12
Knowledge gaps in extracorporeal blood purification: what would be required for its successful application in septic shock?
David, S., Rimmelé, T., Joannidis, M., Girardis, M., Pickkers, P., Nielsen, N. D., Buhlmann, A., Molnár, Z., Ostermann, M., Kielstein, J. T., et al. (2025) · Intensive Care Medicine Experimental · doi:10.1186/s40635-025-00819-8 · Cited by 11
New Frontiers in Sepsis-Induced Acute Kidney Injury and Blood Purification Therapies: The Role of Polymethylmethacrylate Membrane Hemofilter
Stasi, A., Franzin, R., Caggiano, G., Losapio, R., Fiorentino, M., Alfieri, C., Gesualdo, L., Stallone, G., & Castellano, G. (2023) · Blood Purification · doi:10.1159/000528685 · Cited by 11
Canadian Association of Paediatric Nephrologists COVID-19 Rapid Response: Guidelines for Management of Acute Kidney Injury in Children
Alabbas, A., Kirpalani, A., Morgan, C., Mammen, C., Licht, C. P. B., Phan, V., Wade, A., Harvey, E., Zappitelli, M., Clark, E. G., et al. (2021) · Canadian Journal of Kidney Health and Disease · doi:10.1177/2054358121990135 · Cited by 11
Hemoadsorption in critically ill patients with or without COVID-19: A word of caution
Putzu, A., & Schorer, R. (2021) · Journal of Critical Care · doi:10.1016/j.jcrc.2021.06.007 · Cited by 11
Hemadsorption
Cutuli, S. L., Grieco, D. L., PASCALE, G. D., & Antonelli, M. M. (2021) · Current Opinion in Anaesthesiology · doi:10.1097/aco.0000000000000953 · Cited by 11
Self-citation
Haemoperfusion with polymyxin B membrane: Recent results for an old debate!
Payen, D. M. (2019) · Anaesthesia Critical Care & Pain Medicine · doi:10.1016/j.accpm.2018.12.010 · Cited by 11
Cost-effectiveness of polymyxin B hemoperfusion for septic shock: an observational study using a Japanese nationwide administrative database
Fujimori, K., Tarasawa, K., & Fushimi, K. (2023) · Journal of Anesthesia Analgesia and Critical Care · doi:10.1186/s44158-023-00087-6 · Cited by 10
Pushing the Boundaries of Hemodialysis: Innovations in Membranes and Sorbents
Vega‐Vega, O., Ronco, C., & Martinez-Rueda, A. J. (2023) · Revista de investigaci�n Cl�nica · doi:10.24875/ric.23000223 · Cited by 10
Catastrophic Streptococcus pyogenes Disease: A Personalized Approach Based on Phenotypes and Treatable Traits
Ruiz‐Rodríguez, J. C., Chiscano‐Camón, L., Maldonado, C., Ruiz‐Sanmartín, A., Martin, L., Bajaña, I., Bastidas, J., López‐Martínez, R., Franco‐Jarava, C., González‐López, J. J., et al. (2024) · Antibiotics · doi:10.3390/antibiotics13020187 · Cited by 11
Adjunctive immunotherapeutic agents in patients with sepsis and septic shock: a multidisciplinary consensus of 23
Girardis, M., Coloretti, I., Antonelli, M. M., Berlot, G., Busani, S., Cortegiani, A., PASCALE, G. D., Rosa, F. G. D., Rosa, S. D., Donadello, K., et al. (2024) · Journal of Anesthesia Analgesia and Critical Care · doi:10.1186/s44158-024-00165-3 · Cited by 15
Self-citation
Simultaneous Removal of Endotoxin and Circulating Histones by Heparin-Grafted Chitosan-Cellulose Composite Microspheres for Multitargeted Hemoperfusion in Septic Blood
Cheng, Y., Chen, Y., Song, T., Jiang, L., He, Y., Li, Y., Zhao, W., & Su, B. (2025) · Biomacromolecules · doi:10.1021/acs.biomac.5c01085 · Cited by 10

Authors: Dellinger, R. P., Bagshaw, S. M., Antonelli, M., Foster, D. M., Klein, D. J., Marshall, J. C., Palevsky, P. M., Weisberg, L. S., Schorr, C. A., Trzeciak, S., Walker, P. M., & for the EUPHRATES Trial Investigators
Affiliations: Cooper University Hospital (US)
University of Alberta (CA)
Università Cattolica del Sacro Cuore (IT)
Spectral Medical Inc, Toronto, Canada
St. Michael's Hospital (CA)
University of Pittsburgh (US)
Corresponding author: Dellinger, R. Phillip
ORCID: Bagshaw, Sean M.
Antonelli, Massimo
Klein, David J.
Marshall, John C.
Palevsky, Paul M.
Weisberg, Lawrence S.
Schorr, Christa A.
Trzeciak, Stephen
Venue: JAMA
Publisher: American Medical Association (AMA)
Published: 2018-10-09
Volume: 320
Issue: 14
Pages: 1455
ISSN: 0002-9955 (ISSN-L)
0098-7484
DOI: 10.1001/jama.2018.14618
PMC: PMC6233793
OpenAlex: W2897735762
Cited by: 502
References: 25
Citations by year: 2026: 73 · 2025: 71 · 2024: 71 · 2023: 70 · 2022: 52 · 2021: 54 · 2020: 63 · 2019: 40 · 2018: 5
FWCI: 31.62
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: JAMA (publishedVersion)
Europe PMC (PubMed Central) (publishedVersion)
PubMed Central (publishedVersion)
PubMed (publishedVersion)
Figshare (submittedVersion)
Leicester Research Archive (University of Leicester) (submittedVersion, other-oa)
Funders: University of Nebraska Medical Center
Memorial Sloan-Kettering Cancer Center
Cleveland Clinic
University of Pittsburgh
East Carolina University
Thomas Jefferson University
Temple University
University of Alberta
Medical Center, University of Pittsburgh
Topics: Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Sepsis Diagnosis and Treatment
Health Sciences › Medicine › Pharmacology (medical) › Antibiotics Pharmacokinetics and Efficacy
Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
Keywords: polymyxin B hemoperfusion, septic shock, endotoxin activity, endotoxemia, 28-day mortality, multiple organ failure, sepsis, critically ill patients, endotoxin activity assay, survival outcomes, sepsis treatment, APACHE II score, multiple organ dysfunction score, sepsis mortality
MeSH terms: Adult, Aged, Anti-Bacterial Agents, Endotoxins, Female, Humans, Male, Middle Aged, Polymyxin B, Shock, Septic, Survival Analysis, Hospital Mortality, APACHE

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Effect of Targeted Polymyxin B Hemoperfusion on 28-Day Mortality in Patients With Septic Shock and Elevated Endotoxin Level: The EUPHRATES Randomized Clinical Trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks